4.7 Article

2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes

Journal

JOURNAL OF NEUROLOGY
Volume 265, Issue 11, Pages 2684-2687

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00415-018-9048-8

Keywords

Clinically isolated syndrome; Multiple sclerosis; Conversion; Diagnostic criteria; Dissemination in space; Dissemination in time; Symptomatic gadolinium enhancing lesion; Oligoclonal bands

Funding

  1. Novartis
  2. Teva
  3. Sanofi Genzyme
  4. Almirall
  5. Associazione Italiana Sclerosi Multipla (AISM)
  6. Genzyme
  7. Bayer Schering
  8. Biogen-Dompe
  9. Boehringer Ingelheim
  10. Lundbeck
  11. Merck-Serono
  12. Sigma-Tau
  13. UCB Pharma
  14. Biogen Idec
  15. Biogen
  16. Merck Serono
  17. Eisai
  18. Sanofi-Aventis
  19. Roche

Ask authors/readers for more resources

Objectives To investigate the impact of the 2017 revisions of McDonald criteria on the diagnosis of multiple sclerosis (MS) in a cohort of patients with clinically isolated syndrome (CIS) and dissemination in space (DIS) of demyelinating lesions. Methods We retrospectively analyzed 137 patients with CIS+DIS from two Italian MS centers. Results Application of the 2017 revisions of McDonald criteria in our cohort led to a diagnosis of MS in 82.5% of the patients who could have not been diagnosed with MS according to the previous criteria at the time of the first demyelinating event. After a follow-up of 3.8 +/- 2.9 years, 85.8% of these patients eventually satisfied also the previous (2010) criteria. Conclusions Application of the 2017 revisions of McDonald criteria results in an earlier diagnosis of MS in a large percentage of CIS patients destined to convert to MS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available